Filing Flows › Integrated Biopharma (INBP) › Q2 FY26
Integrated Biopharma (INBP) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Feb 11, 2026
Integrated Biopharma (INBP) reported revenue of $11.3M for the second quarter fiscal 2026 (Q2 FY26), -11% from a year earlier and -11% from the quarter before. Operating margin was -8.1%, net loss $762K (6.8% of revenue).
Integrated Biopharma, Q2 FY26: revenue $11.3M (-11% year over year), operating margin -8.1%, net loss $762K, operating cash flow $617K. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.3M | -11% | -11% |
| Operating profit | −$914K | -661% | -552% |
| Net earnings | −$762K | -720% | -757% |
| Operating cash flow | $617K | -53% | +207% |
| Free cash flow | $593K | -47% | +245% |
What changed
Revenue was $11.3M in Q2 FY26, down 11% year over year and down 11% from the previous quarter. Contract Manufacturing was the largest line at 97% of revenue. Contract Manufacturing lost $750K year over year (down 6%), 56% of the total change.
Gross margin was 0.3%, down 9.0 points from Q2 FY25. Operating costs exceeded revenue by $914K, an operating margin of -8.1%. Operating expenses fell 3% while revenue fell 11%. The quarter ended with a net loss of $762K, after a profit of $123K the previous quarter.
Operating cash flow was $617K (up 207% year over year). Non-cash charges added back $78K of depreciation and $42K of share-based compensation. Working capital and other items added $1.3M. Capital expenditures of $24K left free cash flow of $593K.
Questions
What was Integrated Biopharma's revenue in the second quarter fiscal 2026?
Integrated Biopharma (INBP) reported revenue of $11.3M for the second quarter fiscal 2026 (Q2 FY26), -11% from a year earlier and -11% from the quarter before.
Was Integrated Biopharma profitable in the second quarter fiscal 2026?
Operating loss was $914K (-8.1% of revenue) and net loss $762K.